Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of IRTC's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Sep 28, 2020
Questions asked 37 each answered in the company's own letter
No closing letter 3 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 37 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 1 of 4 closing letter

Half the closed reviews took 11 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2019

2020-09-28 to 2020-10-09 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-10-09
Controls
After reviewing your response to this comment, we may have additional comments. Item 6. Exhibits, page 70
SEC asked
We note that the certifications filed as Exhibits 31.1 and 31.2 exclude the introductory language regarding internal control over financial reporting in the fourth paragraph and do not include paragraph 4(b). Please amend the filing to provide revised certifications that include the required information.
Rest of the question

You may file an abbreviated amendment that is limited to the cover page, explanatory note, signature page and paragraphs 1, 2, 4 and 5 of the certifications. Refer to Exchange Act Rule 13a-14(a) and Item 601(b)(31) of Regulation S-K. This comment also applies to your Form 10-Q for the quarterly period ended March 31, 2020.

IRTC answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company has revised Exhibits 31.1 and 31.2 of each of the Quarterly Reports to include the introductory language regarding internal control over financial reporting in the fourth paragraph and to include paragraph 4(b).
Read in the reply
In its next report

First report after the company's reply of Oct 6, 2020: 10-Q filed Nov 6, 2020 ↗, against the 10-Q filed Aug 7, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-10-09

Form S-1

2020-08-13 to 2020-08-17 · 1 question · 1 letter from the SEC, 3 from the company
No closing letter
Legal and contingenciesDerivatives and hedging
Registration Statement on Form S-1 filed August 11, 2020 · Choice of Forum, page 26
SEC asked
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” In addition, we note your disclosure on page 26 that only claims brought derivatively under the Exchange Act would be subject to the forum selection clause.
Rest of the question

In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. If this provision does not apply to actions arising under Exchange Act, please revise your prospectus accordingly and also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act.

IRTC answered
In response to the Staff’s comment, the Company has updated the disclosure on pages 15 and 26 of the S-1/A. The Company intends to include the revised disclosure set forth above in future filings to inform investors that the forum selection provision in its certificate of incorporation and bylaws does not apply to any actions arising under the Exchange Act, except for derivative actions brought under the Exchange Act.
Read in the reply

Also in this review: company letter, Aug 17, 2020, company letter, Aug 17, 2020

Form S-1

2016-09-30 to 2016-09-30 · 5 questions · 1 letter from the SEC, 0 from the company
No closing letter
Risk factors
SEC letter of Sep 30, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
From your response to prior comment 1, it appears that you may have sponsored thirdparty researchers named in the prospectus. If so, please file the consent of the named researchers as exhibits to your registration statement. See Rule 436.
IRTC answered

No reply letter found.

Clinical Results and Studies, page 78
SEC asked (2)
We note your revision in response to prior comment 5 indicating that some of the results you present may not be statistically significant. Where you discuss the results of each study, please disclose whether those results are statistically significant or whether the statistical significance of the results was not assessed.
IRTC answered

No reply letter found.

AF Burden as Predictor of Stroke Risk, page 80
SEC asked (3)
It is unclear from your disclosure here and throughout whether your product is used for identifying arrhythmia itself, or if it is used to identify risk factors associated with already-identified arrhythmia. From your disclosure here, it appears that the patch is prescribed for use in arrhythmia-identified patients. Please clarify.
IRTC answered

No reply letter found.

Non-Employee Directors, page 93
SEC asked (4)
Please revise to clarify the business experience of Mr. Talwalkar since May 2014. See Item 401(e) of Regulation S-K.
IRTC answered

No reply letter found.

Exhibits
SEC asked (5)
Please ensure that you file complete exhibits, including all attachments. In this regard, we note, by way of example only, the missing attachments to exhibits 10.21 and 10.31.
IRTC answered

No reply letter found.

Form S-1

2016-03-08 to 2016-10-04 · 30 questions · 2 letters from the SEC, 2 from the company
No closing letter
RevenueResults discussion (MD&A)Risk factorsCritical estimates
Prospectus Cover Page
SEC asked (1)
Refer to the qualitative claims in the center of your graphic under “Addressing Prevalent Healthcare Challenges.” Since these non-graphical statements require significant additional text to qualify and/or explain their meaning, they appear to be inappropriate for a cover-page or gatefold graphic.
Rest of the question

In addition, since you are likewise unable to provide a balanced and meaningful summary of the studies, tests and publications about your products here, please remove textual references to “proven” results.

IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (2)
Refer to the first full paragraph on page 2. With respect to the peer-reviewed articles you reference, please tell us (1) whether they relate exclusively to the studies you discuss later in your disclosure starting on page 79, and if not, what other data they address, (2) whether they are based upon data you provided or that was provided by unrelated third parties and (3) whether there are other peer-reviewed
Rest of the question

articles or other information available about your product, especially those that address any negative findings relating to your product.

IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (3)
Please revise here and throughout to explain why having the “world’s largest repository of ambulatory ECG patient data” would provide you with an advantage, especially in light of the protections provided to individual healthcare data by various state and federal laws.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (4)
Refer to the first full paragraph on page 2. Where you cite numerical or percentage improvements resulting from use of your product, please indicate the baseline data against which you are measuring such improvements.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (5)
Further, when you discuss your clinical studies here and starting on page 79, provide a balanced view by summarizing the studies’ limitations. As examples only, certain studies included a small sample size, and it appears you only compared your product to the Holter monitor, though you indicate it has advantages over event monitors as well.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (6)
Please provide objective support for your statement on page 1 that you believe there to be an existing $1.4 billion market opportunity for your ZIO Service.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Emerging Growth Company Status, page 5
SEC asked (7)
You indicate on page 5 that you are an emerging growth company as defined in the JOBS Act. Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Risk Factors, page 10
SEC asked (8)
Refer to your statement in the first paragraph on page 19 and the last paragraph on page 81 that LifeWatch AG “claim[s] to have [a] patch-based monitor” in its pipeline. It appears that LifeWatch may have recently received FDA approval for a patch-based monitor. Please revise as appropriate.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 44
SEC asked (9)
Please disclose the approximate amount of proceeds that you currently intend to use for each purpose stated in the first sentence of the second paragraph on page 44, consistent with Item 504 of Regulation S-K. You mention that you may use proceeds to sponsor clinical trials and studies.
Rest of the question

Please provide additional details about any trials or studies needed at this time to support continued commercialization of your product or that you view as necessary to your business on a going forward basis.

IRTC answered

No numbered answer found in the reply. Read the reply ↗

Management’s Discussion and Analysis, page 52
SEC asked (10)
Refer to the final paragraph on page 53. Please revise as appropriate to discuss whether you have been able to increase contract pricing in the past and to discuss the basis for your belief that you will be able to increase contract pricing in the future, particularly given the entrance of more competitors to the market.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Revenue, page 55
SEC asked (11)
We assume by “covered lives” you mean users of your product. It is unclear how the term relates to your business, since your product does not appear to be an on-going monitoring device. Please revise to clarify.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Revenue Recognition, page 61
SEC asked (12)
We reference the disclosure that when you cannot reasonably estimate reimbursement, you recognize revenue upon the earlier of notification of payment or when payment is received. Please revise to disclose how you assess whether you can reasonably estimate reimbursement when revenue is recognized on an accrual basis.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Revenue Recognition, page 61
SEC asked (13)
We see that material costs of your product include amortization of the re-usable printed circuit board assemblies, or PCBAs, over the anticipated number of uses of the board. We also note the discussion about PCBA estimates on page F-11. Please tell us why you do not include a discussion of the estimates involved in determining the usage of the PCBAs within Critical Accounting Policies and Estimates.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Stock-Based Compensation, page 62
SEC asked (14)
Please tell us the estimated IPO price range once you have that information. To the extent there is a significant difference between the estimated grant-date fair value of your common shares during the past twelve months and the estimated IPO price range, please discuss for us each significant factor contributing to the difference.
IRTC answered
Determination of Estimated Preliminary Initial Public Offering Price

Range

The Company supplementally advises the Staff that on October 2, 2016, representatives of the lead underwriters presented and discussed a proposed price range for the Company’s initial public offering (“IPO”) and advised the Company that, based on then-current market conditions, they anticipated that they would recommend a preliminary price range of $[***] to $[***] (the “Preliminary Price Range”) per share.
Rest of the answer

The underwriters’ October 2, 2016 recommendation will form the basis for the Preliminary Price Range contained in the preliminary prospectus.

The Company advises the Staff that the Preliminary Price Range represents the Company’s belief of what the indicative price range to be disclosed in the preliminary prospectus will be, except that the preliminary prospectus will take into account a reverse share split of the Company’s common stock that will become effective before the printing of the preliminary prospectus (the

“Reverse Share Split”). Furthermore, the actual indicative price range to be included in the preliminary prospectus is subject to further change, which may result from various factors, including but not limited to then-current market conditions and subsequent business, market and other developments affecting the Company and its markets. The indicative price range and Reverse Share Split to be included in the preliminary prospectus will be included in an amendment to the Registration Statement prior to distribution of any preliminary prospectus to potential investors.

The Company advises the Staff that it anticipates filing its preliminary prospectus on or about [***] before market open and commencing its roadshow as early as such date, with a target pricing date as early as [***].

Stock Option Issuances by the Company since September 23, 2015

To facilitate the Staff’s review, the table below contains a complete list of all grants of options to purchase the Company’s common stock made from September 23, 2015 through the date of this letter (the “Review Period”).

Grant Date

Shares of

Common Stock

Underlying

Options Granted

Exercise

Price

Per

Share

Fair Value

Per Share of Common

Stock for

Financial

Reporting

Purposes at

Intrinsic

Value Per

December 1, 2015

164,000

$

[***]

—

December 15, 2015

1,045,000

*

[***

]

February 9, 2016

96,000

March 25, 2016

54,500

May 23, 2016

362,500

July 26, 2016

90,000

*Subsequent to the date of grant, the Company used the December 2015 Valuation Report (as defined below), which was not available at the time of grant, for the purposes of determining fair value for FAS 123R financial reporting purposes.

Overview of Option Pricing and Fair Value Determinations

The section captioned “Stock-Based Compensation” on pages 63 and 64 of the

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) section of the Registration Statement includes a detailed explanation of the Company’s approach to accounting for stock-based compensation and factors considered by the Company in determining fair value.

As previously disclosed in the Registration

Statement, each time the Company’s Board of Directors (the “Board”) has granted options, the Board has granted those options with an exercise price intended to be equal to the fair value of the underlying common stock on the date of the grant. Given the absence of an active trading market for the Company’s common stock, determining the fair value of the Company’s common stock requires the Company’s Board to make complex and subjective judgments. In doing so, the Company’s Board considered a combination of valuation methodologies as described in the MD&A.

As detailed in the Registration Statement, the Board, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of the Company’s common stock as of the date of each grant, including the following factors:

• contemporaneous valuations of the Company’s common stock prepared by an unrelated third party valuation firm;

the Company’s stage of development;

the rights, preferences and privileges of the Company’s preferred stock relative to those of its common stock;

the Company’s financial condition and operating results, including its revenue, history of net losses and levels of available capital resources;

equity market conditions affecting comparable public companies;

general U.S. market conditions; and the lack of marketability of the Company’s common stock.

The Company and its Board have consistently sought to comply with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “Practice Guide”). Throughout the Review Period, the Company had obtained quarterly contemporaneous independent valuations from an independent valuation firm to assist the Board in making its determination of fair value and to ensure that all relevant business developments were taken into account in making valuation determinations and that the valuations obtained were truly “contemporaneous,” as that term is defined in the Practice Guide. Throughout the Review Period, the Company’s Board consisted of individuals with significant experience in business, finance, investing and significant experience in valuing companies, including determining the fair values of the common stock of such companies. In each instance, the Company’s Board reached its determination of the estimated fair value of the Company’s common stock after discussion and made its determination in good faith, based on the information available on the date of grant, including the contemporaneous valuations mentioned in the MD&A and as described in additional detail below.

Third Party Independent Valuations

The Board believes it made a thorough evaluation of the relevant factors to determine the fair value of the Company’s common stock on each option grant date. The valuations were performed consistent with the guidance and methods outlined in the Practice Guide. A review of the methodology and key assumptions included in the independent third party valuations considered for the purpose of determining the fair value of the Company’s common stock at each option grant date during the Review Period were as follows:

Summary of December 1, 2015 and December 15, 2015 Option Grants

The Company advises the Staff that the Company’s Board determined that the fair value of the underlying shares of common stock for option awards granted on December 1, 2015 and December 15, 2015 (the “December 2015 Grants”) was $[***] per share. At the time of the December 2015 Grants, the Company’s Board carefully considered all relevant information available to it, including the most recent valuation report from its third-party independent valuation firm (the “September 2015 Valuation Report”), which concluded that, as of September 30, 2015, the fair value of shares of the Company’s common stock was $[***] per share. The Board determined that there were no material changes in the Company’s business since September 30, 2015, or in the assumptions upon which the September 2015

Valuation Report was based, that had affected the fair value of its shares of common stock.

The September 2015 Valuation Report used a probability-weighted expected return model (“PWERM”) that incorporated an IPO by March 2016, weighted at 10% (the “Early IPO Scenario”), an IPO by June 2016, weighted at 15% (the “Mid IPO

Scenario”), an IPO by November 2016, weighted at 20% (the “Late IPO Scenario”), an M&A alternative exit following the estimated IPO window around March 2017, weighted at 10% (the “M&A

Scenario”), a sale with no value to common stockholders, weighted at 5% (the “Low Sale Scenario”), and a stay private for an additional two to three years strategy using an option pricing model

(“OPM”) calculation, weighted at 40% (the “Stay Private Scenario”).

The September 2015

Valuation Report estimated the future equity value in each scenario by applying enterprise value to revenue multiples and made appropriate adjustments for projected cash and debt as of the future scenario valuation date. The September 2015 Valuation

Report applied a 15% discount rate to each scenarios’ future equity value to arrive at a present value of equity for each scenario. The 15% cost of equity discount rate was determined using the capital asset pricing model

(“CAPM”). The September 2015 Valuation Report also applied a 10% discount for lack of marketability (“DLOM”) in the Early IPO Scenario, a 13% DLOM in the Mid IPO Scenario, a 16% DLOM in the Late IPO

Scenario, an 18% DLOM in the M&A Scenario and a 32% DLOM in the Stay Private Scenario. Additionally, the September 2015 Valuation Report used the Company’s projections for being cash flow breakeven in [***] and having positive cash flow thereafter, multiples from the 75th percentile of comparable guideline public companies for each of the scenarios, and a future pre-money equity value of [***] in the Late IPO Scenario (estimated future IPO date of November 2016).

Summary of February 9, 2016 and March 25, 2016 Option Grants

The Company advises the Staff that the Company’s Board determined that the fair value of the underlying shares of common stock for option awards granted on February 9, 2016 and March 25, 2016 (the “February/March 2016 Grants”) was $[***] per share. At the time of the February/March 2016 Grants, the Company’s Board carefully considered all relevant information available to it, including the most recent valuation report from its third-party independent valuation firm (the “December 2015 Valuation Report”), which concluded that, as of December 31, 2015, the fair value of shares of the Company’s common stock was $[***] per share. The Board determined that there were no material changes in the Company’s business since December 31, 2015, or in the assumptions upon which the December 2015

The December 2015 Valuation Report also used a PWERM, which incorporated the previous Early

IPO Scenario, weighted at 0%, the Mid IPO Scenario, weighted at 25%, the Late IPO Scenario, weighted at 25%, the M&A Scenario, weighted at 10%, the Low Sale Scenario, weighted at 5%, and the Stay Private Scenario, weighted at 35%.

The December 2015 Valuation Report estimated the future equity value in each scenario by applying enterprise value to revenue multiples and made appropriate adjustments for projected cash and debt as of the future scenario valuation date. The December 2015 Valuation Report applied a 15% discount rate, calculated using CAPM, to each scenarios’ future equity value to arrive at a present value of equity for each scenario. The December 2015 Valuation Report applied a 7% DLOM in the Early IPO Scenario, a 10% DLOM in the Mid IPO Scenario, a 14% DLOM in the Late IPO Scenario, a 17% DLOM in the M&A Scenario and a 28% DLOM in the Stay Private Scenario. Additionally, the December 2015 Valuation Report used the Company’s projections for being cash flow breakeven in [***] and having positive cash flow thereafter, multiples from the 75th percentile of comparable guideline public companies for each of the scenarios, and a future pre-money equity value of [***] in the Late IPO Scenario (estimated future IPO date of November 2016).

Summary of May 23, 2016 and July 26, 2016 Option Grants

The Company advises the Staff that the Company’s Board determined that the fair value of the underlying shares of common stock for option awards granted on May 23, 2016 and July 26, 2016 (the “May/July 2016 Grants”) was $[***] per share. At the time of the May/July 2016 Grants, the Company’s Board carefully considered all relevant information available to it, including the most recent valuation report from its third-party independent valuation firm (the “March 2016 Valuation Report”), which concluded that, as of March 31, 2016, the fair value of the

Company’s shares of common stock was $[***] per share. The Board determined that there were no material changes in the Company’s business since March 31, 2016, or in the assumptions upon which the March 2016 Valuation Report was based, that had affected the fair value of its shares of common stock.

The March 2016 Valuation Report used a PWERM with revised dates that incorporated an IPO by June 2016, weighted at 10% (the “Revised Date Early IPO Scenario”), an IPO by September 2016, weighted at 20% (the “Revised Date Mid IPO Scenario”), an IPO by March 2017, weighted at 15% (the “Revised Date Late IPO Scenario”), the previous M&A Scenario, weighted at 20%, the previous Low Sale Scenario, weighted at 5%, and a revised stay private for an additional two years strategy using an

OPM calculation, weighted at 30% (the “Revised Stay Private Scenario”).

The March 2016 Valuation Report estimated the future equity value in each scenario by applying enterprise value to revenue multiples and made appropriate adjustments for projected cash and debt as of the future scenario valuation date. The March 2016 Valuation Report applied a 14% discount rate, calculated using CAPM, to each scenarios’ future equity value to arrive at a present value of equity for each scenario. The March 2016 Valuation Report also reflected a 7% DLOM in the Revised Date Early IPO Scenario, a 10% DLOM in the

Revised Date Mid IPO Scenario, a 15% DLOM in the Revised Date Late IPO Scenario, a 15% DLOM in the M&A Scenario and a 29% DLOM in the Revised Stay Private Scenario. Additionally, the

March 2016 Valuation Report used the Company’s projections for being cash flow breakeven in [***] and having positive cash flow thereafter, multiples from the 50th percentile of comparable guideline public companies for each of the Revised Date IPO Scenarios and multiples from the 75th percentile of comparable guideline public companies for the M&A Scenario, and a future pre-money equity value of [***] in the Revised Date Mid IPO Scenario (estimated future IPO date of September 2016).

Although not used by the Board in determining the fair value of the Company’s common stock for the May/July 2016 Grants, the Company supplementally advises the Staff that the Company received a valuation report from its third-party independent valuation firm (the “July 2016 Valuation Report”) which concluded that as of July 31, 2016, the fair value of the Company’s shares of common stock was [***] per share. The July 2016 Valuation Report cited declining market conditions between March 31 and July 31, 2016, uncertainty in the IPO market in Q2 2016, later projected IPO and M&A scenario dates for the Company, and an increased probability of fundraising through the sale of the Company’s preferred stock in the near term as reasons for the decline in per share valuation for the Company’s common stock. The July 2016

Valuation Report further determined that the Company had a future pre-money equity value of [***] in the scenario that it conduct its IPO by the end of October 2016.

Other Grant Date Considerations

As noted above, at each option grant date, the Board considered the third party valuations available at the time of determination and other specific objective and subjective factors, including the following factors:

December 2015 Grants

As of September 30, 2015, the Company had not yet hired investment bankers for the IPO process.

The Company achieved revenue and gross margin targets for Q3 2015 and was on budget for year-to-date 2015.

The Company faced collection risks and uncertainties with new product launches.

The Company anticipated increased competition from competitors.

The Company planned to raise capital through a $30 million debt financing in Q4 2015.

There were no significant adverse changes in the business, operations or products that had occurred since June 30, 2015.

February/March 2016 Grants

As of December 31, 2015, the Company had hired investment bankers for the IPO process and held its organizational meeting on December 3, 2015.

The Company achieved revenue and gross margin targets for Q4 2015 and performed on budget for 2015.

The Company raised capital through a $30 million debt financing in Q4 2015.

There were no significant adverse changes in the business, operations or products that had occurred since September 30, 2015.

May/July 2016 Grants

Year-end 2015 performance exceeded target and was on budget.

The Company increased revenue projections for 2016-2017, and management provided 2018 projections for the first time.

The Company held discussions with the lead underwriters in Q1 2016, including a February 9, 2016 meeting with J.P. Morgan at which J.P. Morgan indicated that there had been “limited IPO activity” and

“recent IPO performance has been mixed” and a subsequent March 22, 2016 meeting with J.P. Morgan and Morgan Stanley (collectively, the “Underwriters Meetings”).

The Company had confidentially submitted its registration statement to the SEC for review in Q1 2016 and revised expected dates for a potential IPO until later in 2016 or Q1 2017.

Management discussed an increased likelihood of an M&A Scenario given uncertainty regarding IPO market conditions and the limited IPO activity in Q1 2016 (only eight IPOs across all industries).

The independent valuation firm used a revised list of guideline public companies based on a review of recent IPO market inactivity, revised comparable company criteria and the reports provided at the Underwriters

Meetings.

In March 2016, two secondary transactions in the Company’s common stock of which the Company was aware were executed at $[***] per share, or the fair value per share as determined in the December 2015 Valuation

Report.

There were no significant adverse changes in the business, operations or products that had occurred since December 2015.

Summary

Once the

Company’s IPO became a probable scenario, the Board determined to contingently grant options to purchase the Company’s common stock with a grant date on the effective date of the Registration Statement and with an exercise price equal to the IPO price, as disclosed in the prospectus. The Company advises the Staff that it has not granted any additional options below the IPO price subsequent to those on granted on July 26, 2016 (“the “Most Recent Grant

Date”). The Company believes the difference between the fair value of its common stock as the Most Recent Grant Date and the midpoint of the estimated Preliminary Price Range is the result of the following factors:

Better Market Conditions. The Preliminary Price Range also took into account performance and valuations of companies in August and September 2016 that the lead underwriters expect will be viewed as comparable to the Company, as well as the recent performance of successful initial public offerings of companies outside of the Company’s line of business that the lead underwriters felt may potentially be viewed by investors as comparable.

Increased Probability of an IPO and Substantially Enhanced Liquidity and Marketability of the Company’s Stock. The March 2016 Valuation Report reflected the illiquidity of the Company’s common stock on

March 31, 2016 and the uncertainty of the IPO. The difference between the fair value of the Company’s common stock as of the Most Recent Grant Date and the lower bound of the Preliminary Price Range reflects a discount of approximately

[***]%. Given the proximity to the completion of the Company’s IPO, the Preliminary Price Range assumes a successful offering and represents an estimate of the fair value of the unrestricted, freely tradable stock that would be sold in the public market without discounts for illiquidity and lack of marketability.

Conversion of Preferred Stock. The holders of the Company’s convertible preferred stock currently enjoy substantial economic rights and preferences over the holders of its common stock. In particular, Series

C and Series B can convert to shares of common stock based on the following ratios: 2.25x and 2.0x, respectively, and Series C and Series D have 1.5x liquidation preferences. Furthermore, holders of outstanding convertible preferred stock are entitled to receive liquidation preferences prior to payments to holders of common stock in the event of any liquidation, dissolution or winding-up of the Company. In addition, holders of the Company’s outstanding convertible preferred stock are entitled to receive dividends prior to any dividends declared or paid on any shares of the Company’s common stock. The holders of convertible preferred stock also have anti-dilution protection under certain circumstances and special voting rights. The Preliminary Price Range assumes the conversion of the Company’s convertible preferred stock upon the completion of its IPO. The corresponding elimination of the preferences and rights enjoyed by the holders of such convertible preferred stock results in an increased common stock valuation.

Substantially Enhanced Balance Sheet and Financial Resources. Given the proximity to the completion of the IPO, the Preliminary Price Range assumes a successful offering. A successful offering provides the

Company with (i) proceeds that substantially strengthen the Company’s balance sheet as a result of increased cash, (ii) access to the public company debt and equity markets, and (iii) a ‘currency’ to enable the Company to make strategic acquisitions as the Board may deem appropriate, which are reflected in the valuation reflected in the Preliminary Price Range.

Conclusion

In light of the foregoing, the Company believes that the actions of the Board to estimate the fair value of the Company’s common stock during the Review Period complied with the requirements of the Financial Accounting Standards Board’s Accounting

Standards Codification Topic 718 (formerly Statement of Financial Accounting Standards No. 123(R), Share-Based Payment), the best practices outlined in the Practice Guide, and the Internal Revenue Code of 1986, as amended.

Read in the reply
Business, page 66
SEC asked (15)
Please balance your discussion in the last paragraph on page 66 with a discussion of other comparable technologies on the market that, like the ZIO Service, also do not have the limitations of traditional ambulatory cardiac monitors.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Business, page 66
SEC asked (16)
Please balance your discussion of the limitations of traditional ambulatory cardiac monitors on page 70 and the discussion of the key benefits of your product beginning on pate 71 with a discussion of any limitations of your product.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Business, page 66
SEC asked (17)
Please provide a source for the data depicted in the graph on page 73.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Clinical Results and Studies, page 79
SEC asked (18)
We note that you only discuss a “few” of the clinical studies related to your product. Explain why you chose the ones you discuss and tell us why you think it is appropriate to omit others. Also explain any negative findings in connection with the ones you do not describe.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Clinical Results and Studies, page 79
SEC asked (19)
Refer to the first full paragraph after the chart on page 79. Explain what you mean by “diagnostic yield” and how the number of events cited relates to the benefits of such yield.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Clinical Results and Studies, page 79
SEC asked (20)
Explain why it is appropriate to indicate a percentage advantage of your product over Holter monitor with a 74 person sample size.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Competition, page 81
SEC asked (21)
We note your list of principal competitive factors on pages 81 and 82 and your statement on page 82 that you compete favorably based on these factors. Please balance this discussion by describing for which of these factors you compete less favorably.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Competition, page 81
SEC asked (22)
Please disclose in your discussion of intellectual property on page 82 the duration of each individual patent, as required by Item 101(h)(4)(vii) of Regulation S-K.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Management, page 91
SEC asked (23)
Please indicate which of your directors is currently serving as chair.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Principal Stockholders, page 115
SEC asked (24)
Please identify the natural person or persons who exercise the sole or shared voting and/or dispositive powers.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked (1)
We note in your response to prior comment 2 that none of the principal investigators or primary authors of the peer-reviewed studies were your employees. Please expand your response to tell us whether any of the studies were funded, in part or in whole, by you or any related parties, and whether any related parties participated in the studies, even if they were not the principal investigator or primary author.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 43
SEC asked (2)
We note the revised disclosure in response to prior comment 9 regarding the approximate amount of proceeds intended for each listed purpose. As further requested by prior comment 9, since it appears you may potentially use some of the proceeds to fund clinical studies, please tell us about any trials or studies needed at this time to support continued commercialization of your product or that you view as necessary
Rest of the question

to your business on a going forward basis.

IRTC answered

No numbered answer found in the reply. Read the reply ↗

Management’s Discussion and Analysis, page 50 · Cost of Revenue and Gross Margin, page 51
SEC asked (3)
Refer to your disclosure in the first paragraph on page 53 that increases in your 2015 revenue were due primarily to increases in volume and, “to a lesser extent,” to increases in price. Please quantify the proportion of your increased revenue attributable to volume increases verses price increases.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Value to Payors, page 69
SEC asked (4)
We note your response to our prior comment number 17. Please tell us how you have ensured that the data presented in the study remains current.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Clinical Results and Studies, page 74
SEC asked (5)
We note your response to our prior comment number 20; however, since these are statistics for clinical relevance and not marketing, please explain that the percentage is based upon clinical guidelines rather than a large sample size.
IRTC answered

No numbered answer found in the reply. Read the reply ↗

Clinical Results and Studies, page 74
SEC asked (6)
We note the addition of your discussion of the LIBERTY-HCM study in the third full paragraph on page 76. Please note that reliance on technical terms can hinder an investor’s ability to understand your disclosure.
Rest of the question

In this regard, please revise to clarify your description of the LIBERTY-HCM study so that investors who are unfamiliar with the terms used in this paragraph can understand the purpose and significance of this study as it relates to your product. Please also disclose any results of this study to date.

IRTC answered

No numbered answer found in the reply. Read the reply ↗

Letters without questions

Other letters

UPLOAD and CORRESP
2 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2016-03-08. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.